Michael David Alpert
Works at
Ceo
Sources: reporter.nih.gov
Grants and prizes
National Heart, Lung, and Blood Institute
R44, Non-viral gene therapy to treat and prevent atherosclerosis, R44HL184837, 2026–2027, Aug 24, 2026
National Institute of Allergy and Infectious Diseases
R43, Cpf1-mediated inactivation of an AAV transgene, R43AI136163, 2018, Jan 5, 2018
Sources: reporter.nih.gov